Publications by authors named "Shengyun Hao"
The protective effects of Irbesartan in cognitive impairment in hypertension.
Aging (Albany NY)
March 2024
Article Synopsis
- Vascular cognitive impairment (VCI) is the second most common type of dementia after Alzheimer's, with hypertension as a key factor, yet there are no current treatments for this condition.
- Irbesartan, an angiotensin receptor antagonist, showed potential in mitigating hypertension-induced cognitive issues in a study with Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats.
- The study found that Irbesartan lowered blood pressure and improved cognitive performance in various tests, while also reversing negative biochemical markers associated with cognitive decline and restoring normal cAMP/CREB signaling in the hippocampus.
Article Synopsis
- Atherosclerosis is linked to cardiovascular disease and circular RNAs, particularly circSCAP, play significant roles in its development.
- Researchers conducted various assays to evaluate the expression of RNA and proteins, analyze cell behavior, and assess lipid accumulation and oxidative stress in THP-1 cells treated with oxidized LDL.
- Findings revealed that circSCAP promotes lipid buildup, inflammation, and oxidative stress through the regulation of the miR-221-5p and PDE3B pathway, making it a potential target for therapeutic strategies against atherosclerosis.
Background: ISR remains the major adverse outcome after percutaneous coronary intervention (PCI). MicroRNAs have been demonstrated to be associated with coronary plaque and stable in the blood and can be used as biomarkers/predictors. This study aimed to investigate whether circulating microRNAs could predict in-stent restenosis (ISR).
View Article and Find Full Text PDF